FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,971,382 | -52.3% | 834,324 | -42.8% | 0.02% | -53.7% |
| Q1 2023 | $8,317,913 | +55.2% | 1,459,283 | +174.8% | 0.04% | +36.7% |
| Q4 2022 | $5,358,153 | -54.2% | 531,036 | +1.6% | 0.03% | -52.4% |
| Q3 2022 | $11,711,000 | -1.2% | 522,574 | +9.3% | 0.06% | +3.3% |
| Q2 2022 | $11,849,000 | +39.7% | 478,153 | +118.6% | 0.06% | +27.1% |
| Q1 2022 | $8,480,000 | -46.3% | 218,718 | -19.0% | 0.05% | -44.8% |
| Q4 2021 | $15,805,000 | +114.1% | 270,120 | +116.9% | 0.09% | +81.2% |
| Q3 2021 | $7,382,000 | +742.7% | 124,546 | +1133.3% | 0.05% | +700.0% |
| Q2 2021 | $876,000 | -72.6% | 10,099 | -71.3% | 0.01% | -77.8% |
| Q4 2020 | $3,202,000 | +186.4% | 35,218 | +25.9% | 0.03% | +200.0% |
| Q3 2020 | $1,118,000 | +47.3% | 27,965 | -18.1% | 0.01% | -59.1% |
| Q1 2020 | $759,000 | – | 34,166 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |